[1] Hovind P, Rossing P, Tarnow L, et al. Progression of diabetic nephropathy. Kidney Int, 2001; 59, 702-9. doi:  10.1046/j.1523-1755.2001.059002702.x
[2] Rossing K, Christensen PK, Hovind P, et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int, 2004; 66, 1596-605. doi:  10.1111/j.1523-1755.2004.00925.x
[3] Ⅱ. Incidence and prevalence of ESRD. Am J Kidney Dis, 1999; 34, S40-50.
[4] Burden AC, McNally PG, Feehally J, et al. Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med, 1992; 9, 641-5. doi:  10.1111/dme.1992.9.issue-7
[5] Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population:follow-up of cross sectional health survey. BMJ, 2006; 333, 1047. doi:  10.1136/bmj.39001.657755.BE
[6] Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 2003; 42, 1050-65. doi:  10.1161/01.HYP.0000102971.85504.7c
[7] Fabre J, Balant LP, Dayer PG, et al. The kidney in maturity onset diabetes mellitus:a clinical study of 510 patients. Kidney Int, 1982; 21, 730-8. doi:  10.1038/ki.1982.90
[8] Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339, 229-34. doi:  10.1056/NEJM199807233390404
[9] Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes:a population-level cohort study. Lancet, 2012; 380, 807-14. doi:  10.1016/S0140-6736(12)60572-8
[10] Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, 2001; 286, 421-6. doi:  10.1001/jama.286.4.421
[11] Yokoyama H, Tomonaga O, Hirayama M, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia, 1997; 40, 405-11. doi:  10.1007/s001250050694
[12] Ueda H, Ishimura E, Shoji T, et al. Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care, 2003; 26, 1530-4. doi:  10.2337/diacare.26.5.1530
[13] Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes:the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 2004; 47, 1747-59. doi:  10.1007/s00125-004-1527-z
[14] Lu B, Song X, Dong X, et al. High prevalence of chronic kidney disease in population-based patients diagnosed with type 2 diabetes in downtown Shanghai. J Diabetes Complications, 2008; 22, 96-103. doi:  10.1016/j.jdiacomp.2007.08.001
[15] Yang XL, So WY, Kong AP, et al. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes:Hong Kong Diabetes Registry. Diabetologia, 2006; 49, 2299-308. doi:  10.1007/s00125-006-0376-3
[16] Rubin DB. Multiple Imputation for Nonresponse in Surveys, New York:Wiley. Biometrics, 1989; 45.
[17] Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol, 1999; 28, 964-74. doi:  10.1093/ije/28.5.964
[18] Schemper M, Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics, 2000; 56, 249-55. doi:  10.1111/j.0006-341X.2000.00249.x
[19] Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics, 2005; 61, 92-105. doi:  10.1111/biom.2005.61.issue-1
[20] Royston P. Explained variation for survival models. Stata Journal, 2006; 6, 83-96. http://artax.karlin.mff.cuni.cz/r-help/library/pec/html/R2.html
[21] Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med, 2004; 23, 723-48. doi:  10.1002/(ISSN)1097-0258
[22] Statacorp LP. Stata multiple-imputation reference manual. Stata Press Publication, 2011.
[23] Manttari M, Tiula E, Alikoski T, et al. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension, 1995; 26, 670-5. doi:  10.1161/01.HYP.26.4.670
[24] Thomas GN, Critchley JA, Tomlinson B, et al. Peripheral vascular disease in Type 2 diabetic Chinese patients:associations with metabolic indices, concomitant vascular disease and genetic factors. Diabet Med, 2003; 20, 988-95. doi:  10.1046/j.1464-5491.2003.01046.x
[25] Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy:the RENAAL study. Kidney Int, 2003; 63, 1499-507. doi:  10.1046/j.1523-1755.2003.00885.x
[26] Sawicki PT, Didjurgeit U, Muhlhauser I, et al. Smoking is associated with progression of diabetic nephropathy. Diabetes Care, 1994; 17, 126-31. doi:  10.2337/diacare.17.2.126
[27] Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes:a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis, 2000; 36, 646-61. doi:  10.1053/ajkd.2000.16225
[28] Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int, 2002; 61, 1086-97. doi:  10.1046/j.1523-1755.2002.00213.x
[29] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998; 317, 703-13. doi:  10.1136/bmj.317.7160.703